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Abstract
Background: The World Health Organization (WHO), like many other organisations around the world, has recognised
the need to use more rigorous processes to ensure that health care recommendations are informed by the best available
research evidence. This is the fourth of a series of 16 reviews that have been prepared as background for advice from
the WHO Advisory Committee on Health Research to WHO on how to achieve this.
Objectives: We reviewed the literature on conflicts of interest to answer the following questions:
1. What is the best way to obtain complete and accurate disclosures on financial ties and other competing interests?
2. How to determine when a disclosed financial tie or other competing interest constitutes a conflict of interest?
3. When a conflict of interest is identified, how should the conflict be managed?
4. How could conflict of interest policies be enforced?
Methods: We searched PubMed, the Cochrane Methodology Register and selectively searched for the published
policies of several organizations, We did not conduct systematic reviews ourselves. Our conclusions are based on the
available evidence, consideration of what WHO and other organisations are doing and logical arguments.
Key questions and answers: What is the best way to obtain complete and accurate disclosures on financial
ties and other competing interests?
• Although there is little empirical evidence to guide the development of disclosure forms, minimal or open-ended
formats are likely to be uninformative. We recommend the development of specific, detailed, structured forms that
solicit as much information as possible about the nature and extent of the competing interests.
How to determine when a disclosed financial tie or other competing interest constitutes a conflict of
interest?
• There is no empirical evidence to suggest that explicit criteria are preferable to ad hoc committee decisions when
deciding if a disclosed financial tie is a conflict of interest. However, explicit criteria may make decision-making easier.
When a conflict of interest is identified, how should the conflict be managed?
• Descriptive studies suggest that appropriate management strategies are best determined on a case-by-case basis. Thus,
WHO should use a wide range of management strategies to address disclosed conflicts of interest, with public disclosure
of conflicts associated with each meeting as a minimum and recusal of conflicted individuals as the other extreme.
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How could conflict of interest policies be enforced?
• Although there are no empirical studies of the enforcement of conflict if interest policies, descriptive studies of other 
organizations and institutions suggest that WHO convene a standing committee to review all financial disclosure 
statements prior to the commencement of committee meetings/hearings and to make management recommendations 
when necessary. A standard policy requiring all financial ties to be made public (i.e., recorded into the meeting minutes) 
should reduce the number of problematic cases. In instances where the conflicts seem intractable, a recommendation of 
recusal may be necessary to protect the greater interests of WHO and its constituents.
Background
The World Health Organization (WHO), like many other
organisations around the world, has recognised the need
to use more rigorous processes to ensure that health care
recommendations are informed by the best available
research evidence. This is the fourth of a series of 16
reviews that have been prepared as background for advice
from the WHO Advisory Committee on Health Research
to WHO on how to achieve this.
A conflict of interest exists when an individual's secondary
interests (e.g. personal financial) interfere with or influ-
ence judgments regarding the individual's primary inter-
ests (e.g. patient welfare, education, research integrity).
There is evidence demonstrating the association of finan-
cial ties with a breakdown in research integrity. Recent
studies and reviews have found that industry funding for
research is associated with favourable outcomes for the
sponsor [1-5]. Financial ties of investigators with their
sponsors (stock ownership, consulting income, etc.) are
also associated with favourable research outcomes for the
sponsor [5]. This scholarly evidence has been accentuated
by lay media stories documenting how financial conflicts
of interest have led to biased and even dangerous research
(e.g., [6,7]). Biased research may be intentional or unin-
tentional [8] and may result from damaged objectivity at
multiple stages in the research process, including concep-
tualization of the question, design or conduct of the
research, interpretation of the results, and publication (or
not) of the research [9,10]. Regardless of its source, the
bias associated with financial and other conflicts of inter-
est may damage both the public's and other researcher's
trust in science [11]. The type of conflict most likely to
affect the public's trust is a financial conflict where the sci-
entist tends to gain financially from a particular research
outcome [11-16], although other competing interests,
such as professional advancement, are important. Con-
flict of interest policies are designed to protect the integ-
rity of research and decision-making processes through
disclosure and transparency.
The following report relies heavily on published research
related to conflicts of interest in the context of U.S. aca-
demic research and U.S. and U.K. biomedical journals
because there is little empirical research from other areas.
In this paper we address the following questions:
• What is the best way to obtain complete and accurate
disclosures on financial ties and other competing inter-
ests?
￿ How to determine when a disclosed financial tie or
other competing interest constitutes a conflict of interest?
￿ When a conflict of interest is identified, how should the
conflict be managed?
￿ How could conflict of interest policies be enforced?
Related questions about group composition, consultation
and group processes are addressed in another paper in this
series [17,18].
What WHO is doing now
Expert Advisory Panel members are currently required to
disclose "all circumstances that could give rise to a poten-
tial conflict of interest as a result of their membership on
an expert committee." [19]
According to the WHO Declaration of Interests for WHO
Experts, a conflict of interest occurs when "the expert or
his/her partner (a spouse or other person with whom s/he
has a similar close personal relationship), or the adminis-
trative unit with which the expert has an employment
relationships, has a financial or other interest that could
unduly influence the expert's position with respect to the
subject matter being considered." An apparent conflict of
interest exists when the existence of an interest could
result in the expert's objectivity being questioned by oth-
ers, and a "potential conflict of interest exists with an
interest which any reasonable person could be uncertain
whether or not should be reported" [20].
The Declaration identifies 5 types of financial and other
interests that must be disclosed by all experts, including
proprietary interests and patents, shares or bonds in a
related commercial entity, employment or consultancies,
paid work or research, and grants or fellowships from a
commercial entity that has an interest in the subject-mat-
ter or work of the committee. [20]Health Research Policy and Systems 2006, 4:16 http://www.health-policy-systems.com/content/4/1/16
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We are not aware of specific WHO documents providing
guidance on how to avoid or manage conflicts of interest,
and we know of no processes required to ensure that the
committees discuss potential conflicts of interest on a
case-by-case basis and handle them appropriately. There
may be some variability in how departments collect and
manage the disclosed information.
In October 2005, the WHO Office of Legal Counsel rec-
ommended a set of proposed revisions to the existing con-
flict of interest procedures that are similar to the
recommendations in our report. These revisions would
clarify the definition of a conflict of interest, include rec-
ommendations for avoiding situations that might result
in conflicts of interest, and expand the relationships and
affiliations that must be disclosed. The draft guidelines
also recommend that a determination be made as to
whether the expert's declared interest is insignificant,
clearly significant, or potentially significant (para. 26).
Suggestions for making this determination include weigh-
ing the nature and extent of the interest, the context of the
work, and the importance of the expert's contribution
(para. 29). The draft Guidelines also suggest three options
for managing a conflict: 1) continue with public disclo-
sure of the interest; 2) limit the expert's involvement; or 3)
exclude the expert from the meeting or work altogether
(para. 30)[21]
The draft guidelines also include a requirement that WHO
experts disclose ties to the tobacco industry. This recom-
mendation is in response to a 2000 commissioned report
investigating the influence of the tobacco industry on
WHO's global tobacco control policies. That report rec-
ommended that WHO formally vet prospective experts,
consultants, and advisers for possible conflicts of interest
related to the tobacco industry and that staff should be
barred from having links with the tobacco industry [22].
In 2003, WHO's hypertension guidelines were revised in
response to criticism about possible conflicts of interest
among expert members [23].
What other organizations are doing
Many organizations recognize the importance of protect-
ing against actual and potential conflicts of interest and
require special employees, advisory committee members,
and participants to disclose their financial ties to the
organization. For example, the US Food and Drug Admin-
istration (FDA), the Cochrane Collaboration, the UK
National Institute for Health and Clinical Excellence
(NICE), and the US National Academies of Science all
require advisory committee members and other special
participants to disclose financial relationships, including
research sponsorship, equity ownership, consulting fees,
honoraria, related to the work or topic of the committee.
These organizations use a structured disclosure form to
solicit information; they employ different standards for
determining conflicts of interest and for managing them
(see below).
Methods
The methods used to prepare this review are described in
the introduction to this series [24] Briefly, the key ques-
tions addressed in this paper were vetted amongst the
authors and the ACHR Subcommittee on the Use of
Research Evidence (SURE). We searched PubMed and the
Cochrane Methodology Register [25] for existing system-
atic reviews and relevant methodological research that
address these questions. We did not conduct systematic
reviews ourselves. The answers to the questions are our
conclusions based on the available evidence, considera-
tion of what WHO and other organisations are doing, and
logical arguments.
For this review, we searched PubMed for original qualita-
tive and quantitative research using the terms "conflicts of
interest" and "disclosure" and the Cochrane Methodology
Register using "conflict of interest". We searched the refer-
ence lists of all relevant publications, consulted references
from the Council of Medical Editors meeting on disclo-
sure (Sept 2004) and selectively searched for the pub-
lished policies of several organizations, including the
Cochrane Collaboration, NICE, FDA, and National Acad-
emies of Science [26-30].
Findings
Our database searches did not yield any systematic
reviews of conflict of interest or financial disclosure poli-
cies. We found several systematic reviews of literature
examining the association between commercial sponsor-
ship and outcomes favorable to the sponsor and the
financial ties of investigators and favorable outcomes. We
also found a number of empirical studies of particular
aspects of industry involvement in science and medicine,
case studies and commentaries.
What is the best way to obtain complete and accurate 
disclosures on financial ties and other competing interests?
We were unable to identify any randomized, controlled
trials or other rigorous studies evaluating different meth-
ods for obtaining conflict of interest disclosures. Biomed-
ical journals gather financial interest statements from
authors of submitted manuscripts in three ways: 1) mini-
mal requests about authors' professional and financial
affiliations that may be perceived to have biased the pres-
entation of results; 2) detailed instructions that request
authors to describe all involvements with organizations or
entities with direct financial interest in the subject matter
of the study; and 3) detailed, structured checklists that
require authors to declare specific interests [31]. Krimsky
and others are critical of the utility of minimal and open-Health Research Policy and Systems 2006, 4:16 http://www.health-policy-systems.com/content/4/1/16
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ended requests [31]. Bero et al. caution that simple disclo-
sure requests may not reveal the nature and extent to
which commercial interests exert influence over the scien-
tific process [32].
The Cochrane Collaboration Steering Group members,
the Food and Drug Administration advisory committee
members, NICE, and the National Academies use struc-
tured disclosure forms and request information on a
range of financial ties, including research funding, paid
consultancies, honoraria, equity holdings, gifts, patents,
and royalties. The Cochrane Collaboration also requests
information on positions of management in a related
entity, including service as a director, officer, partner, trus-
tee or employee, and information on outstanding loans
from the entity. The National Academies of Science
request disclosure of any position that would give the
individual access to confidential information, including
patient records, classified and proprietary information.
NICE requests information regarding an individual's pri-
vate practice that could be affected by the outcome or dis-
cussion of a particular matter or product.
There is considerable variation along other dimensions of
disclosure as well. These include:
￿ When disclosures should be made: Upon appointment
to the committee? Prior to the start of committee work?
Under each agenda item? At the start of each committee
meeting?
￿ What level of financial interest should be disclosed: Any
amount (>US$0)? Over US$250/per year in annual
income? Over US$10,000 in equity holdings? Exact
amounts or ranges (i.e., US$1000–$5000)?
￿ What period of time should be covered by the disclo-
sure: The current calendar year? Past 12 months? Past 5
years? Past 5 years and future 2 years?
￿ Who should the disclosure cover: Individual only? Indi-
vidual's spouse and children? Individual's institution?
How to determine when a disclosed financial tie or other 
competing interest constitutes a conflict of interest?
Few organizations or institutions provide explicit guide-
lines for determining when a particular financial relation-
ship constitutes a conflict of interest. The Association of
American Medical Colleges prohibits financial relation-
ships between principal investigators and commercial
sponsors of clinical trials, but uses a "rebuttable presump-
tion" clause to allow the prohibition to be waived when
the benefits of the research outweigh the risks of the con-
flict of interest [33]. The US National Institutes of Health
and National Science Foundation establish financial
thresholds for disclosure – $10,000 in annual income or
5% equity ownership in a commercial entity related to the
scientific work [34].
The US FDA does not prohibit financial relationships
among its Advisory Committee members and regularly
issues waivers for disclosed conflicts of interest when 1)
"the disqualifying financial interest is not so substantial
that it is likely to affect the integrity of an employee's serv-
ices to the government;" and 2) the "need for the
employee's services outweighs the potential conflicts of
interest" [29]. In making these determinations, the FDA
evaluates "the type of interest creating the disqualifica-
tion; the identity of the person whose financial interest is
at issue; the dollar value of the disqualifying financial
interest including its value in relationship to the individ-
ual's overall assets; the nature and importance of the indi-
vidual's role in the matter, including the extent to which
the employee is called upon to exercise discretion; the sen-
sitivity of the matter; and the need for the employee's serv-
ices in the particular matter" [29].
These criteria are in line with the criteria used by Univer-
sity of California conflict of interest committees. In the
only empirical study to date of how conflict of interest
committees define and manage disclosed financial rela-
tionships of faculty investigators [35], found that commit-
tees typically examined the nature of the proposed
scientific work (basic or applied), the overlap between
paid activities and the research topic, the length and dollar
amount of the relationship between the investigator and
the commercial entity, and the degree to which the inves-
tigator could be seen as independent of the company's
interests.
The overall lack of explicit criteria for determining which
relationships constitute conflicts of interest reflect a com-
mon perception that these decisions should be made on
an ad hoc basis and that the organization must always bal-
ance its own needs for the particular expertise of the indi-
vidual with the needs of the public (in terms of advancing
scientific discovery as well as trust in the scientific proc-
ess). Little is known, however, about the needs and under-
standings of the public in this regard. The few studies we
have identified to date provide evidence of both favorable
and unfavorable reactions of the public [36,37]. Profes-
sionals with industry ties are more supportive of financial
ties than those without industry ties. Investigators recog-
nize general risks of conflicts of interest, but not for them-
selves. Investigators tend to support disclosure of financial
ties, although there is evidence that disclosure leads to
more critical review of research findings [38]. Schroter
and colleagues showed that the overall importance, rele-
vance, validity, and believability of studies disclosingHealth Research Policy and Systems 2006, 4:16 http://www.health-policy-systems.com/content/4/1/16
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competing interests were rated lower by readers than
those without competing interests. [39]
When a conflict of interest is identified, how should the 
conflict be managed?
The only empirical studies of management decisions in
conflicts of interest detail a number of management strat-
egies that are commonly used by university conflict of
interest committees [35,40]. These possible management
strategies include: disclosure of the financial tie(s) in pub-
lications and public presentations; reducing equity hold-
ings to below 5%; altering consulting agreements to
ensure separation between consulting and research work;
eliminating the financial tie; appointing oversight com-
mittees to review the scientific process and resulting
research; and recusal. Government and professional soci-
ety guidelines recommend that institutions "manage" the
financial conflicts of interest of their researchers. Disclo-
sure of financial ties in all publications and presentations
is the most frequently used management strategy [40-43].
Scientific journals are also encouraging disclosure as a
way of dealing with financial conflicts of interest [44],
however, the adequacy of disclosures in scientific articles
has been questioned [32,45]. Even when financial spon-
sorship is disclosed, few studies describe the role of the
sponsor [46]. A study of the relationships between
authors of clinical practice guidelines and the pharmaceu-
tical industry found considerable interaction between
guideline authors and the pharmaceutical industry [47];
another study found that clinical practice guidelines pub-
lished in journals almost never published conflict of inter-
est statements along with the guidelines [48].
The FDA in 2002 issued draft guidance amending their
disclosure regulations related to Advisory Committee
members. The draft guidance now requires that Advisory
Committee members granted waivers of their conflicts of
interest will have the nature and magnitude of their con-
flicts of interest disclosed and read into the public record
at the start of the committee hearings. [28]. NICE, which
is currently reviewing its policies on disclosure and con-
flicts of interests, recommends that "members should
declare all interests at the beginning of all appraisals" and
that those declarations of interests be kept in files availa-
ble for public scrutiny or are recorded in the minutes of
the meeting [27]. The Cochrane Collaboration publishes
the declarations of interests of its Steering Group mem-
bers [26].
Although disclosure of financial ties is becoming more
accepted within the scientific and policy communities,
there are widely varying opinions about the adequacy of
disclosure as a management strategy for financial conflicts
of interest. Some critics of disclosure feel that it is unnec-
essary and can taint the reputation of "good" researchers
[49,50]. Others believe that "the key to avoiding conflict
of interest is public disclosure" [51]. Studies that disclose
industry sponsorship have a systematic bias towards out-
comes that favor the sponsor [3,5,52,53], so, therefore,
disclosure does not eliminate bias. Although disclosure
does not eliminate the association of research funding
with outcomes favorable to the sponsor, many argue that
it can minimize perceived conflicts of interest.
Additional research is necessary to be able to evaluate dif-
ferent methods for defining conflicts of interest and to
determine their relative impact on the decision-making
capabilities of the organization.
How should conflict of interest policies be enforced?
There is no empirical evidence evaluating the enforcement
of conflict of interest policies. Most organizations and aca-
demic institutions convene a standing or ad hoc commit-
tee to review financial interest disclosures and, where
deemed necessary, recommend management strategies.
The US FDA vets all financial disclosure statements
through a multi-stage process, beginning with initial
review, followed by consultation with the individual and
an FDA official, review by the FDA Ethics staff, and final
approval by the appointing official. The FDA operates
under federal regulations and thus has the power to
enforce its decisions [28,29]. The Cochrane Collaboration
directs unclear cases of financial disclosure for reviews to
a "Funding Arbiter" who convenes a standing panel of
four to give guidance [26].
Further work
There is currently a lack of empirical evidence regarding
the most effective ways to determine the existence of con-
flicts of interest, manage conflicts of interest, and enforce
conflict of interest policies. Additional research is neces-
sary to evaluate different methods for defining conflicts of
interest and to determine their relative impact on the deci-
sion-making capabilities of the organization. WHO's pro-
posed draft recommendations (October 7, 2005)
represent a more rigourous evaluation of conflict of inter-
est because it requires more complete disclosure, clearer
standards for evaluating conflicts of interest, and explicit
management strategies.
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